Platform Overview
EVIIVE is the next generation biomarker discovery platform delivering precise diagnostics in majority of immuno-oncology (IO) diseases by breaking personalized medicine barriers.
Unlike static biomarkers, EVs reveal dynamic immune-tumor and immune-metabolic interactions — enabling more precise treatment selection, response prediction, and longitudinal monitoring. Our proprietary antibody panels and analytical engine deliver clinically meaningful insights from just a small volume of plasma.
Unlike static biomarkers, EVs reveal dynamic immune-tumor and immune-metabolic interactions — enabling more precise treatment selection, response prediction, and longitudinal monitoring. Our proprietary antibody panels and analytical engine deliver clinically meaningful insights from just a small volume of plasma.
Unlike static biomarkers, EVs reveal dynamic immune-tumor and immune-metabolic interactions — enabling more precise treatment selection, response prediction, and longitudinal monitoring. Our proprietary antibody panels and analytical engine deliver clinically meaningful insights from just a small volume of plasma.
IMPASS/IMPACT
IMPASS/IMPACT
IMPASS/IMPACT
Single EV discovery technology developing precision diagnostics for cancers with real & high unmet needs.
IMPASS
IMmune PAthogenesis Surveillance System for immune profiling and subpopulation stratification
Our platform begins with high-dimensional immune profiling from blood, using flow cytometry and machine learning to resolve immune cell-derived EV subpopulations. This step identifies distinct patient subgroups based on immune activity, treatment responsiveness, and biomarker expression. The resulting IMPASS profiles can already function as a standalone diagnostic readout—offering stratification power for clinical trials and treatment decisions.
IMPASS
IMmune PAthogenesis Surveillance System for immune profiling and subpopulation stratification
Our platform begins with high-dimensional immune profiling from blood, using flow cytometry and machine learning to resolve immune cell-derived EV subpopulations. This step identifies distinct patient subgroups based on immune activity, treatment responsiveness, and biomarker expression. The resulting IMPASS profiles can already function as a standalone diagnostic readout—offering stratification power for clinical trials and treatment decisions.
IMPASS
IMmune PAthogenesis Surveillance System for immune profiling and subpopulation stratification
Our platform begins with high-dimensional immune profiling from blood, using flow cytometry and machine learning to resolve immune cell-derived EV subpopulations. This step identifies distinct patient subgroups based on immune activity, treatment responsiveness, and biomarker expression. The resulting IMPASS profiles can already function as a standalone diagnostic readout—offering stratification power for clinical trials and treatment decisions.
IMPACT
IMmune PAthogenesis Curated Target for mechanistic insights and therapeutic discovery
Building on the subpopulations identified in IMPASS, the IMPACT module applies multi-omics (RNA, DNA, proteomics) to reveal the molecular signatures driving immune phenotypes. These insights go beyond diagnostics—unlocking new therapeutic targets, resistance pathways, and patient-specific mechanisms that inform drug development and personalized immunotherapy design.
IMPACT
IMmune PAthogenesis Curated Target for mechanistic insights and therapeutic discovery
Building on the subpopulations identified in IMPASS, the IMPACT module applies multi-omics (RNA, DNA, proteomics) to reveal the molecular signatures driving immune phenotypes. These insights go beyond diagnostics—unlocking new therapeutic targets, resistance pathways, and patient-specific mechanisms that inform drug development and personalized immunotherapy design.
IMPACT
IMmune PAthogenesis Curated Target for mechanistic insights and therapeutic discovery
Building on the subpopulations identified in IMPASS, the IMPACT module applies multi-omics (RNA, DNA, proteomics) to reveal the molecular signatures driving immune phenotypes. These insights go beyond diagnostics—unlocking new therapeutic targets, resistance pathways, and patient-specific mechanisms that inform drug development and personalized immunotherapy design.
Our Performance
Our Performance
Our Performance
Value creation by personalized diagnostics: IODx ensures every patient receive the right treatment to maximize chances of complete cure.
97%
97%
97%
*
*
*
Accuracy in predicting IO response
Accuracy in predicting IO response
Accuracy in predicting IO response
80%
80%
80%
*
*
*
Cure success rate
Cure success rate
Cure success rate
* Initial pilot study data and projected estimation.
“Most current biomarkers rely on indirect signals. We’re working with something more immediate—extracellular vesicles—as a way to observe biology closer to how it actually behaves.”
Publications
Publications
Publications
Modelling liver cancer microenvironment using a novel 3D culture system
Modelling liver cancer microenvironment using a novel 3D culture system
Modelling liver cancer microenvironment using a novel 3D culture system
Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures
Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures
Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures
Modular cytosine base editing promotes epigenomic and genomic modifications
Modular cytosine base editing promotes epigenomic and genomic modifications
Modular cytosine base editing promotes epigenomic and genomic modifications
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Serum extracellular vesicles profiling is associated with COVID-19 progression and immune responses
Serum extracellular vesicles profiling is associated with COVID-19 progression and immune responses
Serum extracellular vesicles profiling is associated with COVID-19 progression and immune responses
Assessing Extracellular Vesicles in Human Biofluids Using Flow-Based Analyzers
Assessing Extracellular Vesicles in Human Biofluids Using Flow-Based Analyzers
Assessing Extracellular Vesicles in Human Biofluids Using Flow-Based Analyzers
Intercellular Epigenomic Signalling via Extracellular Vesicles During B Cell Maturation
Intercellular Epigenomic Signalling via Extracellular Vesicles During B Cell Maturation
Intercellular Epigenomic Signalling via Extracellular Vesicles During B Cell Maturation